Add-On Daclizumab Treatment May Be Better In Reducing Multiple Sclerosis Disease Activity Than Interferon Beta Alone

An article published Online First and in the April edition of The Lancet Neurology reports that add-on daclizumab treatment might reduce multiple sclerosis disease activity more than standard interferon beta treatment alone. The article is the work of Dr John W Rose, Neurovirology Research Laboratory, VA Medical Center, Salt Lake City, Utah and University of Utah, USA, and colleagues…

More: continued here

Filed under: Multiple Sclerosis on February 22nd, 2010